Literature DB >> 12865399

Emergence of fluoroquinolone resistance among Bacteroides species.

Yoav Golan1, Laura A McDermott, Nilda V Jacobus, Ellie J C Goldstein, Sydney Finegold, Lizzie J Harrell, David W Hecht, Stephen G Jenkins, C Pierson, Richard Venezia, Jack Rihs, Paul Iannini, Sherwood L Gorbach, David R Snydman.   

Abstract

BACKGROUND: Several newer generation fluoroquinolones have demonstrated good in vitro activity against Bacteroides species; particularly when first introduced. However, resistance of Bacteroides to quinolones appears to be increasing.
MATERIALS AND METHODS: From 1994 to 2001, consecutive non-duplicated Bacteroides isolates from clinical specimens in 12 US hospitals were sent to the Tufts anaerobe laboratory for identification and susceptibility testing. NCCLS recommended methodology for testing was employed. Breakpoints of 8 mg/l for trovafloxacin and 4 mg/l for moxifloxacin were used to examine susceptibility trends.
RESULTS: In total, 4434 isolates were analysed. The geometric mean MIC increased significantly for clinafloxacin, trovafloxacin and moxifloxacin. Resistance to trovafloxacin (breakpoint of 8 mg/l) and moxifloxacin (breakpoint of 4 mg/l) increased from 8% to 25% and from 30% to 43%, respectively. Increased resistance was observed for all Bacteroides species, for all sites of isolation, and in 11 of 12 participating hospitals. Bacteroides vulgatus and isolates from decubitus ulcers were associated with increased resistance. During 2001, trovafloxacin and moxifloxacin resistance among blood isolates was 27% and 52%, respectively. The association between increased resistance and year of isolation remained significant after adjustment for hospital, species and site of isolation.
CONCLUSIONS: Fluoroquinolone resistance among Bacteroides isolated in the US has markedly increased during the years 1994 to 2001. High rates of resistance among blood isolates are of particular concern.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865399     DOI: 10.1093/jac/dkg320

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

1.  Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.

Authors:  Mihaela Peric; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 2.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

3.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 4.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.

Authors:  Carmen Betriu; Esther Culebras; María Gómez; Fátima López; Iciar Rodríguez-Avial; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

6.  In vitro activity of ten antibiotics, including tigecycline, against Bacteroides species in Austria.

Authors:  A J Grisold; I Wendelin; E Presterl; R B Raggam; L Masoud; A Badura; E Marth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

7.  Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Authors:  Alan R Noel; Karen E Bowker; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

8.  In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.

Authors:  Reiner Schaumann; Matthias Funke; Eva Janssen; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

Review 9.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

10.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.